Ovarian suppression plus tamoxifen: a Long-Term bet against breast cancer recurrence

NCT ID NCT07735897

Not yet recruiting Disease control Sponsor: MedicalExcellence Source: ClinicalTrials.gov ↗

First seen Jul 30, 2026 · Last updated Jul 31, 2026 · Updated 1 time

Summary

This study follows young women with hormone-sensitive breast cancer who stayed premenopausal or resumed menstruation after chemotherapy. Researchers are investigating whether adding two years of ovarian function suppression to standard tamoxifen therapy can lower the chance of cancer returning over the long term. The goal is to see if this combination improves survival beyond 10 years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ovarian function suppression (OFS) added to tamoxifen
What this could lead to: If successful, this could confirm that adding temporary ovarian suppression to tamoxifen reduces long-term recurrence risk in young breast cancer survivors.
What could go wrong: This is a long-term follow-up study, not a new treatment test. The added suppression may cause menopausal side effects and may not improve survival for all.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER HORMONE RECEPTOR POSITIVE BREAST CANCER

Contacts and locations

Locations

Asan Medical Center

Seoul, Sondpagu, 05505, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.